Reasonably-likely surrogate endpoints for drug development in pre-cirrhotic Metabolic-dysfunction Associated Steatohepatitis (MASH) are histologically defined, requiring accurate measurements at trial entry and completion.
Histopathologist scoring (MASLD Activity Score (MAS) and fibrosis stage (F)) can both exhibit inter- and
intra -observer variation.
AI models (PathAI AIM-MASH and HistoIndex qFIB) may assist in improving scoring consistency.
Aim: Independently assess the performance of these AI tools compared to expert histopathologists in liver
biopsy samples from across Europe.
Conference
EASL (European Association for the Study of the Liver) Congress 2025
View Poster